Special Issue

Targeting the □-Catenin/Wnt Signaling for Cancer Therapy

Message from the Guest Editor

The Wnt signalling pathway plays a critical role in cell proliferation, migration, polarity and self-renewal at all stages of life, from early development during embryonic stages to adult tissue homeostasis. Consequently, aberrant and disarrayed Wnt signalling is observed in the majority of cancers, and therefore, Wnt signalling components are attractive therapeutic targets when considering the treatment of various cancers. Natural antagonists of the Wnt pathway, were also made use of to trigger apoptosis in cancer cells. Studies on repurposing existing drugs have shown that nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of developing colorectal cancer by lowering the levels of nuclear □-catenin and triggering its degradation. These recent developments in this field and the concomitant understanding of the Wnt/B-catenin signaling pathways have kindled new-found hope for cancer treatment. This Special Issue, entitled "Targeting □-catenin/Wnt Signalling for Cancer Therapy", aims to sum up and highlight the latest fundamental, clinical and conceptual developments in this field.

Guest Editor

Dr. Corinne Prévostel

Institut de Recherche en Cancérologie de Montpellier (IRCM), University of Montpellier, ICM, INSERM U1194, Montpellier, France

Deadline for manuscript submissions

closed (25 March 2024)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed

mdpi.com/si/153591

Pharmaceuticals
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)

MDPI